
Iovance Biotherapeutics has seen its stock price move sharply in recent years, which puts fresh attention on whether the current valuation lines up with the scale of its sales. For anyone looking at Iovance today, the key issue is how that share price stacks up against the revenue base supporting it. The stock has returned 400.0% over the past year, which raises a direct question about how much sales performance can underpin that kind of move. The business model, focused on developing and...
























